Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.

Lucchetta RC, Riveros BS, Pontarolo R, Radominski RB, Otuki MF, Fernandez-Llimos F, Correr CJ.

Clinics (Sao Paulo). 2017 May;72(5):317-324. doi: 10.6061/clinics/2017(05)10. Review.

2.

Exposure-response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development.

Han S, Jeon S, Hong T, Lee J, Bae SH, Park WS, Park GJ, Youn S, Jang DY, Kim KS, Yim DS.

Drug Des Devel Ther. 2015 Sep 9;9:5185-94. doi: 10.2147/DDDT.S85435. eCollection 2015.

3.

An Intensive Lifestyle Intervention Is an Effective Treatment of Morbid Obesity: The TRAMOMTANA Study-A Two-Year Randomized Controlled Clinical Trial.

Burguera B, Jesús Tur J, Escudero AJ, Alos M, Pagán A, Cortés B, González XF, Soriano JB.

Int J Endocrinol. 2015;2015:194696. doi: 10.1155/2015/194696. Epub 2015 Jul 15.

4.

Safety of antiobesity drugs.

Cheung BM, Cheung TT, Samaranayake NR.

Ther Adv Drug Saf. 2013 Aug;4(4):171-81. doi: 10.1177/2042098613489721.

5.

Treatment options for obesity and potential therapies on the horizon.

Motycka CA, St Onge E, Miller SA.

P T. 2011 May;36(5):282-301. No abstract available.

6.

Rise and fall of anti-obesity drugs.

Li MF, Cheung BM.

World J Diabetes. 2011 Feb 15;2(2):19-23. doi: 10.4239/wjd.v2.i2.19.

7.

Sibutramine on cardiovascular outcome.

Scheen AJ.

Diabetes Care. 2011 May;34 Suppl 2:S114-9. doi: 10.2337/dc11-s205. Review. No abstract available.

8.

Emerging role of GLP-1 receptor agonists in the treatment of obesity.

Neff LM, Kushner RF.

Diabetes Metab Syndr Obes. 2010 Jul 20;3:263-73.

9.

Tackling obesity: new therapeutic agents for assisted weight loss.

Karam J, McFarlane S.

Diabetes Metab Syndr Obes. 2010 Apr 26;3:95-112.

10.

Obesity in adults.

Delaet D, Schauer D.

BMJ Clin Evid. 2011 Mar 17;2011. pii: 0604. Review.

11.

No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight.

Smith DL Jr, Robertson HT, Desmond RA, Nagy TR, Allison DB.

Int J Obes (Lond). 2011 May;35(5):652-7. doi: 10.1038/ijo.2010.247. Epub 2010 Nov 16.

12.

Memantine reduces consumption of highly palatable food in a rat model of binge eating.

Popik P, Kos T, Zhang Y, Bisaga A.

Amino Acids. 2011 Feb;40(2):477-85. doi: 10.1007/s00726-010-0659-3. Epub 2010 Jun 23.

13.

The Treatment of Obesity and Its Co-occurrence with Substance Use Disorders.

Vanbuskirk KA, Potenza MN.

J Addict Med. 2010 Mar;4(1):1-10. doi: 10.1097/ADM.0b013e3181ce38e7.

14.

Decision modeling to estimate the impact of gastric bypass surgery on life expectancy for the treatment of morbid obesity.

Schauer DP, Arterburn DE, Livingston EH, Fischer D, Eckman MH.

Arch Surg. 2010 Jan;145(1):57-62. doi: 10.1001/archsurg.2009.240.

15.

Pharmacotherapy for obesity.

Li M, Cheung BM.

Br J Clin Pharmacol. 2009 Dec;68(6):804-10. doi: 10.1111/j.1365-2125.2009.03453.x.

16.

Editorial for BJCP Special Obesity Edition.

Park A.

Br J Clin Pharmacol. 2009 Dec;68(6):801-3. doi: 10.1111/j.1365-2125.2009.03582.x. No abstract available.

17.

Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.

Talbot PS, Bradley S, Clarke CP, Babalola KO, Philipp AW, Brown G, McMahon AW, Matthews JC.

Neuropsychopharmacology. 2010 Feb;35(3):741-51. doi: 10.1038/npp.2009.182. Epub 2009 Nov 4.

18.

Treatment of obesity in primary care practice in the United States: a systematic review.

Tsai AG, Wadden TA.

J Gen Intern Med. 2009 Sep;24(9):1073-9. doi: 10.1007/s11606-009-1042-5. Epub 2009 Jun 27. Review.

19.

The use of sibutramine in the management of obesity and related disorders: an update.

Tziomalos K, Krassas GE, Tzotzas T.

Vasc Health Risk Manag. 2009;5(1):441-52. Review.

20.

Pharmacogenetics: potential role in the treatment of diabetes and obesity.

Vella A, Camilleri M.

Expert Opin Pharmacother. 2008 May;9(7):1109-19. doi: 10.1517/14656566.9.7.1109. Review.

Supplemental Content

Support Center